L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
Atopic Dermatitis
Atopic dermatitis is characterised by reduced skin barrier function and skin hydration.1 Skin barrier dysfunction promotes the development and increases the severity of atopic dermatitis.2 Studies have also demonstrated AD is associated with reduced ceramide levels, especially longer-chain ceramides like ceramide 1, and decreased levels of long-chain free fatty acids.1,3-5
Patients With AD Present With Lower Levels of Ceramides 1 & 35
In a study that compared ceramide content in healthy patients to patients with AD with active lesions, patients with AD exhibited significantly lower ceramide amounts.5
A CeraVe Routine Significantly Reduced AD Symptoms7
Protocol: In a randomised study, 151 subjects (118 subjects over 12) with mild to moderate atopic dermatitis (AD) used the CeraVe Hydrating Cleanser and Moisturising Cream regimen twice daily for 6 weeks. A dermatologist assessed treatment outcomes by comparing AD severity at baseline (day 0) versus the end of treatment (day 42).
Featured Products
Help Your Patients With Atopic Dermatitis Manage Their Flare-Ups
Understand the triggers and explore tips for improving skin symptoms.
Restore the Skin Barrier and Improve Atopic Dermatitis
Explore the benefits of CeraVe Moisturising Cream for your patients with atopic dermatitis.
REFERENCES: 1. Proksch E, Jensen JM, Elias PM. Skin lipids and epidermal differentiation in atopic dermatitis. Clin Dermatol. Mar-Apr 2003;21(2):134-44. doi:10.1016/s0738-081x(02)00370-x 2. Sahle FF, Gebre-Mariam T, Dobner B, Wohlrab J, Neubert RH. Skin diseases associated with the depletion of stratum corneum lipids and stratum corneum lipid substitution therapy. Skin Pharmacol Physiol. 2015;28(1):42-55. 3. Ishikawa J, Narita H, Kondo N, et al. Changes in the ceramide profile of atopic dermatitis patients [letter]. J Invest Dermatol. 2010;130:2511-2514. 4. Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal protein-bound ω-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002;119:166-173. 5. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78(1):27-30. 6. Schachner LA, Blume-Peytavi U, Andriessen A, et al. Expert consensus on ceramides containing skincare in newborns and infants and potential mitigation of atopic dermatitis. Ital J Dermatol Venerol. 2022;157(1):23-32. doi:10.23736/S2784-8671.21.07172-3 7. Lynde CW, Andriessen A. A cohort study on a ceramide-containing cleanser and moisturizer used for atopic dermatitis. Cutis. 2014;93(4):207-213.